Using the “Cubic Effect” to Drive Cell and Gene Therapy Commercialization

Contract partners must help innovator biotechs consider manufacturability as early as possible in development. This requires focusing on technical and operational performance, as well as cost.

The cell and gene therapy industry is at a major inflection point, as therapies move out of clinical trials and into the commercial market. As more therapies are commercialized and become established, demand for cell and gene therapies will grow, leading to vast changes in patient care.

Read this article in BioPharm International’s Outsourcing Resources February 2020 eBook.

Article Details

BioPharm International
eBook: Outsourcing Resources, February 2020
February 2020
Pages: 12–15

Citation

When referring to this article, please cite it as A. Santagostino, “Using the “Cubic Effect” to Drive Cell and Gene Therapy Commercialization," BioPharm International Outsourcing Resources eBook (February 2020).

Articles in this issue

over 5 years ago

Article

Lyophilization Services Gain Ground Amid Growing Biologics Market

over 5 years ago

Article

Biopharma Contract Market Update

over 5 years ago

Article

Building Strategic Relationships with CROs

over 5 years ago

Article

Digitalization: A CDMO’s Perspective

over 5 years ago

Article

More Capacity and Technology Translate to More Options

over 5 years ago

Article

Sourcing Success in Cell and Gene Therapy Development

over 5 years ago

Article

Growth in Biologics Market Inspires Outsourcing

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Subscribe Now!